Rifaximin stimulates nitrogen detoxification by PXR‐independent mechanisms in human small intestinal organoids
Open Access
- 20 December 2022
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 43 (3) , 649-659
Abstract
Background and Aims: Recurrent hepatic encephalopathy (HE) is characterized by hyperammonaemia in combination with neuropsychiatric abnormalities and is treated with lactulose and rifaximin. Rifaximin is a pregnane X receptor (PXR) agonist with low systemic and high intestinal bioavailability. The mechanisms by which it alleviates HE are unclear. We used human small intestinal (hSI) organoids to study whether rifaximin, via PXR activation, affects the epithelial biotransformation machinery, and to gain understanding of its low systemic availability.Methods: We generated PXR knockdown hSI organoids via lentiviral delivery of short hairpin RNAs. Organoids were cultured for 24 h with rifaximin or rifampicin. RNA‐sequencing and metabolomics were performed to analyse gene expression and amino acid metabolism. Luminal rifaximin was quantified by photospectrometry.Results: Treatment of wild‐type hSI organoids with rifaximin resulted in >twofold differential expression of 131 genes compared to DMSO. These effects were largely PXR independent and related to amino acid metabolism. Rifaximin decreased expression of glutaminase‐2 and increased expression of asparagine synthetase and solute carrier 7A11, thereby increasing intracellular glutamine and asparagine concentrations, indicating active ammonia detoxification. Rifaximin was apically excreted into the lumen in an ATP binding cassette B1 (ABCB1)‐dependent manner.Conclusions: Rifaximin—after uptake into enterocytes—stimulates intracellular nitrogen detoxification by PXR‐independent mechanisms. Active apical excretion of rifaximin by ABCB1 into the intestinal lumen explains its low systemic bioavailability. Our study implies that rifaximin, next to modulation of the microbiome, has direct effects on ammonia scavenging in the human small intestinal epithelium.Keywords
Funding Information
- ZonMw (015.015.013, 09150181910029, 848017009)
This publication has 49 references indexed in Scilit:
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CARAdvanced Drug Delivery Reviews, 2010
- Sensitive and Rapid Method for Amino Acid Quantitation in Malaria Biological Samples Using AccQ•Tag Ultra Performance Liquid Chromatography-Electrospray Ionization-MS/MS with Multiple Reaction MonitoringAnalytical Chemistry, 2009
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical PotentialChemotherapy, 2005
- Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathyJournal of Hepatology, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Glutamine Extraction by the Gut Is Reduced in Patients with Depleted Gastrointestinal CancerAnnals of Surgery, 1997
- Porcine intestinal ammonia liberation: Influence of food intake, lactulose and neomycin treatmentJournal of Hepatology, 1988